Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers – ESEMPiO study

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136(5), e359–e386 (2015).
  Medline CASGoogle Scholar
• 2 Jordan MA, Kamath K, Manna T et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol. Cancer Ther. 4(7), 1086–1095 (2005). • Describes the peculiar mechanism of action of eribulin.
  Medline CASGoogle Scholar
• 3 Okouneva T, Azarenko O, Wilson L, Littlefield BA, Jordan MA. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol. Cancer Ther. 7(7), 2003–2011 (2005).
  Google Scholar
• 4 Dabydeen DA, Burnett JC, Bai R et al. Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol. Pharmacol. 70(6), 1866–1875 (2006).
  Medline CASGoogle Scholar
• 5 Kuznetsov G, Towle MJ, Cheng H et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res. 64(16), 5760–5766 (2004).
  Medline CASGoogle Scholar
• 6 Cortes J, O'Shaughnessy J, Loesch D et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a Phase 3 open-label randomised study. Lancet 377(9769), 914–923 (2011). •• Describes the pivotal trial on efficacy and safety of eribulin treatment in metastatic breast cancer.
  Medline CASGoogle Scholar
• 7 Kaufman PA, Awada A, Twelves C et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 33(6), 594–601 (2015).
  Medline CASGoogle Scholar
• 8 Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 291(22), 2720–2726 (2004). •• Analyzes the population enrolled in clinical trial and identifies potential underinvestigated population.
  Medline CASGoogle Scholar
• 9 Freedman RA, Foster JC, Seisler DK et al. Accrual of older patients with breast cancer to alliance systemic therapy trials over time: protocol A151527. J. Clin. Oncol. 35(4), 421–431 (2017).
  MedlineGoogle Scholar
• 10 Watanabe J, Ito Y, Ohsumi S et al. Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study. Invest. New Drugs 35(6), 791–799 (2017).
  Medline CASGoogle Scholar
• 11 Quaquarini E, Sottotetti F, D'Ambrosio D et al. Eribulin across multiple lines of chemotherapy: a retrospective study on quality of life and efficacy in metastatic breast cancer patients. Future Oncol. 13(11S), 11–23 (2017).
  CASGoogle Scholar
• 12 Garrone O, Montemurro F, Saggia C et al. Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial – a multicenter retrospective study of eribulin in real life. Springerplus 5, 59 (2016). • Describes efficacy and safety of eribulin in real-world.
  MedlineGoogle Scholar
• 13 Lorusso V, Cinieri S, Latorre A et al. Efficacy and safety of eribulin in taxane-refractory patients in the ‘real world’. Future Oncol. 13(11), 971–978 (2017).
  CASGoogle Scholar
• 14 Gamucci T, Michelotti A, Pizzuti L et al. Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study. J. Cancer 5(5), 320–327 (2014).
  Medline CASGoogle Scholar
• 15 de Nonneville A, Sabatier R, Gonçalves A et al. Safety and efficacy of eribulin for 'real-world' older patients with metastatic breast cancer. J. Geriatr. Oncol. 9(3), 281–283 (2018).
  MedlineGoogle Scholar
• 16 Bonotto M, Gerratana L, Poletto E et al. Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist 19(6), 608–615 (2014). • Discusses the role of overall survival and progression-free survival as clinical end points in clinical trials.
  MedlineGoogle Scholar
• 17 Twelves C, Cortes J, Vahdat L et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two Phase 3 studies. Breast Cancer Res. Treat. 148(3), 553–561 (2014). •• Analyzes the pooled data from pivotal trials and offers a comprehensive insight on eribulin treatment in selected patients.
  Medline CASGoogle Scholar
• 18 Iizumi S, Shimoi T, Tsushita N et al. Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study. BMC Cancer 17(1), 819 (2017).
  MedlineGoogle Scholar